title: [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives].
abstract: Triple-negative breast cancer (TNBC), as defined by the absence of estrogen and progesterone receptor expression, as well as the lack of HER2 overexpression/amplification, corresponds to 15% of breast cancer and represents an aggressive form of the disease. TNBC are frequently confounded with basal subtype in the molecular classification of breast cancer and also share some similarities with BRCA1-mutated tumors. Epidemiological and clinical characteristics are distinct from other subtypes, including a younger age at diagnosis, a higher risk of relapse in spite of increased chemosensitivity, and a higher incidence of lung and brain metastatic relapses. Conventional cytotoxics remain the mainstay of current systemic management but recent evaluation of more targeted therapeutics, including specific cytotoxics (such as the use of platinum salts), PARP and EGFR inhibition, and antiangiogenics have been performed, providing contrasted but rather disappointing results. Recent data indicate that TNBC represent a heterogeneous entity composed of multiple and distinct molecular subtypes, which should deserve specific targeted therapeutics.
authors.affiliation: Institut Paoli-Calmettes, oncologie médicale, 232, boulevard Sainte-Marguerite, 13009 Marseille, France. goncalvesa@ipc.unicancer.fr
authors.forename: Anthony
authors.initials: A
authors.lastname: Gonçalves
authors.forename: Renaud
authors.initials: R
authors.lastname: Sabatier
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Charafe-Jauffret
authors.forename: Marine
authors.initials: M
authors.lastname: Gilabert
authors.forename: Magali
authors.initials: M
authors.lastname: Provansal
authors.forename: Carole
authors.initials: C
authors.lastname: Tarpin
authors.forename: Jean-Marc
authors.initials: JM
authors.lastname: Extra
authors.forename: Patrice
authors.initials: P
authors.lastname: Viens
authors.forename: François
authors.initials: F
authors.lastname: Bertucci
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D004260:DNA Repair / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D005260:Female; D006801:Humans; D058990:Molecular Targeted Therapy / Q000379:methods; D009363:Neoplasm Proteins / Q000378:metabolism; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism; D009626:Terminology as Topic; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D066246:ErbB Receptors; D009363:Neoplasm Proteins; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
keywords: EGFR; PARP; basal; bevacizumab; platinum; subtypes; triple-negative breast cancer